HPN-217 *
HPN-217 is a B cell maturation antigen (BCMA)-targeting Tri-specific
T cell Activating Construct (TriTAC®).
HPN-217 is being
developed by Harpoon Therapeutics through Phase 1/2 clinical trials.
AbbVie has an option to license worldwide exclusive rights to HPN-217
after completion of the Phase 1/2 trial. Upon exercise of the option,
AbbVie will conduct all future clinical development, manufacturing and
commercialization activities.
Type of Molecule
BiologicTarget
CD3-BCMAProduct Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted, Approved) |
|---|---|---|
| Multiple Myeloma in Relapse | n/a |
Phase 1
|